First graph, first sentence of release should read: ...Wednesday, March 7, 2012. (sted: ...Thursday, March 7, 2012.).
The corrected release reads:
AMAG PHARMACEUTICALS, INC. TO HOST CONFERENCE CALL ON MARCH 7, 2012 AT 4:30 P.M. ET TO DISCUSS FERAHEME CLINICAL TRIAL RESULTS
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report preliminary results from the first of two phase III clinical trials of Feraheme for the treatment of iron deficiency anemia regardless of the underlying cause after the U.S. financial markets close on Wednesday, March 7, 2012. The announcement will be followed by a conference call and webcast at 4:30 p.m. ET during which management will discuss the company’s results of this study.To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 8:30 p.m. ET on March 7, 2012 through midnight March 12, 2012. To access a replay of the conference call, dial (855) 859-2056. The pass code for the live call and the replay is 59989211. The call will be webcast and accessible through the Investors section of the Company’s website at www.amagpharma.com. The webcast replay will be available from approximately 8:30 p.m. ET on March 7, 2012 through midnight April 7, 2012. About AMAG Pharmaceuticals, Inc. AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. AMAG manufactures and sells Feraheme® (ferumoxytol) Injection for intravenous use. For additional company or product information, please visit www.amagpharma.com or http://feraheme.com. Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV